Psychedelic-Assisted Psychotherapies: A Policy Perspective

CPD

Planning Committee Disclosure - No relevant relationships All members of the PESI, Inc. planning committee have provided disclosures of financial relationships with ineligible organizations and any relevant non-financial relationships prior to planning content for this activity. None of the committee members had relevant financial relationships with ineligible companies or other potentially biasing relationships to disclose to learners.  For speaker disclosures, please see the faculty biography.

Handouts

Speaker

Victor Cabral, MSW, LSW, CCTP-I Related seminars and products

---

Victor Cabral, MSW, LSW, CCTP-I, (He/Him/His) is a collaborative and strategic leader who is making an impact on historical inequalities in his community and across the United States. Victor is the Founder of Dreamers of the Day, LLC, and serves as the Director of Policy and Regulatory Affairs for Fluence International Inc., a company that provides evidence-based training in psychedelic therapy and integration services to clinicians across the globe. Before joining Fluence, Victor served as Deputy Director for the Pennsylvania Governor’s Office of Advocacy and Reform where he co-led the implementation of the Trauma-Informed PA Plan, helped establish the first Racial Day of Healing in Pennsylvania history, and developed free trauma trainings for Pennsylvanians in collaboration with BIPOC mental health and trauma, and psychedelic medicine. He is a Licensed Social Worker and practicing psychotherapist in Pennsylvania with training in Internal Family Systems, Psychedelic-Assisted Psychotherapy and Psychedelic Integration.
 

Speaker Disclosures:
Financial: Victor Cabral is the Director of Policy and Regulatory Affairs at Fluence. He receives a speaking honorarium from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Victor Cabral is the Justice, Equity, Diversity, and Inclusion Co-Chair for the American Psychedelic Practitioners Association.

 

Objectives

1. Develop understanding of a brief history of psychedelic drug policy. 
2. Analyze the FDA approval process and breakthrough designation and DEA scheduling. 
3. Differentiate the various phases in the process of approval and where MDMA, Psilocybin, and Ketamine presently fall in this process.
4. Formulate comprehension of the main policy issues currently facing the field of psychedelic-assisted therapy. 
5. Debate the implications for practice and identify at least 1 way they can support the successful adoption of these new therapies.

Outline

• History of Psychedelic Drug Policy 
• FDA approval process, breakthrough designation, and DEA scheduling 
• Psychedelic medicines currently being studied and/or used in therapy 
• Main policy issues in the field of psychedelics 
• Implications for practice and ways to be involved as clinicians

Target Audience

• Counsellors
• Marriage & Family Therapists
• Nurses
• Nurse Practitioners
• Physicians
• Psychologists
• Social Workers
• Other Behavioral Health Professionals

Reviews